8results about How to "Avoid cross reaction" patented technology

The invention belongs to the technical field of luminescence imaging detection, and particularly relates to an electrochemical luminescence imaging detection platform based on a closed bipolar electrode array and application. Comprising a sensor and a detection unit, a bipolar electrode array unit comprises an insulating substrate, an anode region and a cathode region, the anode region and the cathode region are isolated from each other and are of the same structure, and each anode region or each cathode region is provided with a plurality of independent holes which are arrayed in parallel; gold nanoparticles are loaded in a plurality of independent open pores of the parallel array in the anode region, and a Ru (bpy) 32 < + >-TPA system is constructed; au / g-C3N4 composite materials are loaded in a plurality of independent open pores of the parallel array in the cathode region, and an Au / g-C3N4-K2S2O8 system is constructed. According to the invention, based on the bipolar electrode array unit, the terpyridyl ruthenium and the gold / graphite phase carbon nitride are used as different illuminants to realize capture and quantitative analysis for synchronous detection of acetaminophen and rutin, and the detection accuracy and high-throughput analysis are ensured.

This invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein, comprising: a PTGS1 capture antibody, an unlabeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a blocking buffer, a washing buffer, and a stop solution; the IgG secondary antibody specifically binds to the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody that specifically binds to the linear epitope A of human PTGS1 protein, the amino acid sequence of which is SEQ ID NO:1, corresponding to amino acids 271-282 of human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody that specifically binds to the B epitope of human PTGS1 protein; the amino acid sequences of the B epitope at the A epitope do not overlap and do not constitute steric hindrance. This kit avoids the conserved homologous region between PTGS1 and its homologous protein PTGS2, ensuring the accuracy of the capture antibody recognition, and uses an indirect detection mode with enzyme-labeled goat anti-mouse IgG secondary antibody to achieve signal cascade amplification, significantly improving detection sensitivity.

The application discloses a method for improving the sensitivity of RPA-CRISPR-Cas12a detection and application thereof in one-tube detection of chikungunya virus, and relates to the technical field of biology.The full-length crRNA is reformed to form a truncated crRNA (Truncate crRNA), the non-key region is accurately shortened, the space-time regulation of Cas protein activity is realized, and the truncated crRNA plays a key role in CRISPR molecular detection (such as an RPA-CRISPR-Cas12a system). The method can significantly improve the specificity of RPA-CRISPR-Cas12a detection, effectively avoid cross-reaction, inhibit non-specific early activation, significantly reduce background signals, and provide an optimization strategy for developing a molecular diagnostic technology with higher sensitivity.

The invention provides a Notch1 regulation and control method based on a Notch1 super enhancer, relates to the technical field of biomedicine, and has the technical key points that two Notch1 super enhancer sequences are found through research, and the Notch1 super enhancer sequences are named as Notch1-AB and Notch1-CD. According to the application, Notch1-AB and Notch1-CD super enhancers are found and defined as specific key elements for regulating Notch1 high expression in vascular endothelial cells for the first time, and the two regulation paths are cut off through inhibitor inhibition or a gene editing technology, so that efficient and stable down-regulation of Notch1 and target genes thereof is realized, tissue cross reaction caused by direct targeting of Notch1 receptors is avoided, and the Notch1 and target genes thereof can be efficiently and stably regulated. The treatment specificity and safety are obviously improved; the regulation and control mode can adapt to multiple scenes such as conventional treatment and precision medical treatment, vascular diseases and tumors such as atherosclerosis and diabetic retinopathy can be covered, and the application limitation of existing Notch targeted therapy is broken through.

The application discloses a probe primer group, a kit and a detection method for detecting European dodder, wherein the probe primer group comprises an upstream primer Ce-rbcL-F, a downstream primer Ce-rbcL-R and a TaqMan probe Ce-rbcL-P; the nucleotide sequence of the upstream primer Ce-rbcL-F is shown as SEQ ID NO. 1; the nucleotide sequence of the downstream primer Ce-rbcL-R is shown as SEQ ID NO. 2; and the nucleotide sequence of the TaqMan probe Ce-rbcL-P is shown as SEQ ID NO. 3. The primer probe group is designed based on a specific region of the rbcL gene of European dodder, and specific identification of European dodder can be realized by combining an optimized real-time fluorescent PCR reaction system and conditions, namely, the application has the characteristics of rapidness, strong specificity, high identification accuracy, effectively solves the problem that near relatives are difficult to distinguish in traditional morphological identification, and avoids false positive misjudgment. Compared with traditional morphological identification and conventional PCR, the application also has the characteristics of high detection efficiency, short time consumption, simple operation and wide applicability, and can be applied to not only professional laboratory accurate identification, but also practical application of scenarios such as primary quarantine and field monitoring.

The invention discloses a probe for marking gill tissue neuronal cells of macrobrachium hainanense and application of the probe, and belongs to the technical field of biology. The nucleotide sequence of the probe is as shown in SEQ ID NO. 1. According to the method, the probe is designed by screening and utilizing the specific high-expression gene AChE of the macrobrachium hainanense gill tissue neuronal cells for the first time, so that accurate in-situ labeling of the cells can be realized, and cross reaction with non-neuronal cells is effectively avoided. Through a fluorescence in situ hybridization (FISH) technical process, neuronal cells are mainly distributed in a gill axis, only a small part of neuronal cells are distributed in gill filaments, and an AChE gene expression signal is enhanced under alkalinity stress, which indicates that the gene can be used as an alkali-resistant molecular marker. According to the invention, the blank of the technology for marking the neuronal cells of the gill tissue of the crustacean is filled, an important genetic target and a technical means are provided for breeding a new strain of the high-alkali-resistant crustacean, and the method has a wide application prospect.

The application belongs to the technical field of targeted adenovirus, and particularly relates to a nanobody specifically combined with adenovirus Fiber protein and application thereof, and the nanobody 252A7, an amino acid sequence of which is shown as SEQ ID NO. 2. The nanobody 252A7 provided by the application can specifically recognize and combine with Fiber proteins of various serotypes of adenovirus (such as HAdV-3, HAdV-4, HAdV-7, HAdV-55), solves the technical bottleneck that traditional antibodies are difficult to recognize the conserved epitope of Fiber protein and lack broad spectrum, can effectively distinguish adenovirus from other common respiratory viruses (such as RSV, SARS-CoV-2), avoids cross reaction, and improves the accuracy and reliability of clinical etiology diagnosis. The nanobody of the application can be used for developing high-sensitivity immunological detection reagents (such as ELISA, immunochromatography, chemiluminescence, etc.), and has potential application value in the fields of targeted therapy and molecular imaging.

The invention discloses a neutralizing monoclonal antibody for resisting feline panleucopenia virus and application of the neutralizing monoclonal antibody, and belongs to the technical field of bioengineering. The antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and amino acid sequences of the heavy chain variable region (VH) and the light chain variable region (VL) are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2; the antibody is an IgG2a subtype and kappa light chain, can specifically bind to FPV VP2 protein, and effectively neutralizes infection of an F81 cell by an FPV-ZZ20230 strain under the dilution ratio of 1: 64. The invention also provides nucleic acid molecules (SEQ ID NO: 8-9) for coding the antibody, an expression vector, a host cell and a preparation method. The antibody can be used for preparing medicines for preventing or treating feline panleucopenia, and can also be used as a detection antibody for ELISA (enzyme-linked immuno sorbent assay), Western blot or indirect immunofluorescence (IFA) diagnostic kits. The antibody is clear in structure and high in neutralizing activity, does not need to be preserved by hybridoma, and has good clinical application and industrialization prospects.